Literature DB >> 1815341

Protective immunity to entamoeba histolytica infection in subjects with antiamoebic antibodies residing in a hyperendemic zone.

G Choudhuri1, V Prakash, A Kumar, S K Shahi, M Sharma.   

Abstract

To investigate the relationship between amoebic gut infection and the presence of serum antiamoebic antibodies in a community where amoebiasis is highly endemic, a cross-sectional population survey was conducted covering 982 subjects in 2 adjacent villages in rural India. E. histolytica was detected in fecal smears in 18.1% (88/487) and antiamoebic antibodies by micro-ELISA in 28.7% (251/874) subjects. In 450 subjects in whom there was no clinical evidence of invasive amoebic disease or history of ingestion of antiamoebic drugs in the previous year and from whom both stool and matched serum samples were obtained, correlation of gut infection with seropositivity was attempted. Seropositivity in 80 cyst passers (23.8%) was significantly lower than in 370 non-cyst passers (35.1%; p less than 0.05). Conversely the rate of gut infection with E. histolytica was lower in seropositive subjects (19/149; 12.8%) as compared to seronegative subjects (61/301; 23%, p less than 0.05). In the population where E. histolytica infection was highly endemic, the rate of gut infection with the parasite was inversely related to seropositivity. Our data suggests that invasive E. histolytica infection (mostly asymptomatic) evokes good gut immunity in the host with clearing of the parasite from the colon and/or resistance to reinfection. High prevalence rate of amoebic antibodies indicates good "herd" immunity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1815341     DOI: 10.3109/00365549109024306

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  10 in total

1.  Seropositivity for and intestinal colonization with Entamoeba histolytica and entamoeba dispar in individuals in northeastern Brazil.

Authors:  L L Braga; Y Mendonca; C A Paiva; A Sales; A L Cavalcante; B J Mann
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

2.  Diagnosis of amebic liver abscess and intestinal infection with the TechLab Entamoeba histolytica II antigen detection and antibody tests.

Authors:  R Haque; N U Mollah; I K Ali; K Alam; A Eubanks; D Lyerly; W A Petri
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

Review 3.  Laboratory diagnosis of amebiasis.

Authors:  Mehmet Tanyuksel; William A Petri
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

Review 4.  Amebic infection in humans.

Authors:  Gourdas Choudhuri; Murali Rangan
Journal:  Indian J Gastroenterol       Date:  2012-08-19

Review 5.  Host-pathogen interaction in amebiasis and progress in vaccine development.

Authors:  C D Huston; W A Petri
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

6.  Intestinal antilectin immunoglobulin A antibody response and immunity to Entamoeba dispar infection following cure of amebic liver abscess.

Authors:  Jonathan I Ravdin; Mohamed D Abd-Alla; Seth L Welles; Selvan Reddy; Terry F H G Jackson
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

7.  Diagnosis of intestinal amoebiasis by using nested polymerase chain reaction-restriction fragment length polymorphism assay.

Authors:  Krishna Khairnar; Subhash Chandra Parija; Ravisankar Palaniappan
Journal:  J Gastroenterol       Date:  2007-08-24       Impact factor: 7.527

8.  Entamoeba histolytica autochthonous isolates from mentally retarded Italian patients.

Authors:  S Gatti; C Cevini; L Marchi; S Novati; M Scaglia
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

9.  A novel surface protein of Trichomonas vaginalis is regulated independently by low iron and contact with vaginal epithelial cells.

Authors:  V Mundodi; A S Kucknoor; T-H Chang; J F Alderete
Journal:  BMC Microbiol       Date:  2006-01-31       Impact factor: 3.605

10.  Evaluation of the C-Terminal Fragment of Entamoeba histolytica Gal/GalNAc Lectin Intermediate Subunit as a Vaccine Candidate against Amebic Liver Abscess.

Authors:  Xiangyang Min; Meng Feng; Yue Guan; Suqin Man; Yongfeng Fu; Xunjia Cheng; Hiroshi Tachibana
Journal:  PLoS Negl Trop Dis       Date:  2016-01-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.